Literature DB >> 27499080

Virus persistence and recrudescence after Ebola virus disease: what are the risks to healthcare workers?

N E MacDermott1, D G Bausch2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27499080     DOI： 10.1016/j.jhin.2016.07.004

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN： 0195-6701            Impact factor:   3.926


× No keyword cloud information.
  7 in total

1.  A Quantitative Framework for Defining the End of an Infectious Disease Outbreak: Application to Ebola Virus Disease.

Authors:  Bimandra A Djaafara; Natsuko Imai; Esther Hamblion; Benido Impouma; Christl A Donnelly; Anne Cori
Journal:  Am J Epidemiol       Date:  2021-04-06       Impact factor: 4.897

2.  Reflections on the Ebola Public Health Emergency of International Concern, Part 2: The Unseen Epidemic of Posttraumatic Stress among Health-care Personnel and Survivors of the 2014-2016 Ebola Outbreak.

Authors:  Lorenzo Paladino; Richard P Sharpe; Sagar C Galwankar; Farhad Sholevar; Christine Marchionni; Thomas J Papadimos; Elisabeth Paul; Bhakti Hansoti; Michael Firstenberg; Manish Garg; Mindy Watson; Ric A Baxter; Stanislaw P Stawicki
Journal:  J Glob Infect Dis       Date:  2017 Apr-Jun

3.  A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.

Authors:  Georgi Shukarev; Benoit Callendret; Kerstin Luhn; Macaya Douoguih
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

4.  Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.

Authors:  Logan Banadyga; Wenjun Zhu; Shweta Kailasan; Katie A Howell; Krzysztof Franaszek; Shihua He; Vinayakumar Siragam; Keding Cheng; Feihu Yan; Estella Moffat; Wenguang Cao; Anders Leung; Carissa Embury-Hyatt; M Javad Aman; Xiangguo Qiu
Journal:  mBio       Date:  2021-01-12       Impact factor: 7.867

5.  Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model.

Authors:  Ha-Na Lee; Ian L McWilliams; Aaron P Lewkowicz; Kaliroi Engel; Derek D C Ireland; Logan Kelley-Baker; Seth Thacker; Pedro Piccardo; Mohanraj Manangeeswaran; Daniela Verthelyi
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

6.  Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.

Authors:  James Logue; Kaylie Tuznik; Dean Follmann; Greg Grandits; Jonathan Marchand; Cavan Reilly; Yeya Dit Sadio Sarro; James Pettitt; Eric J Stavale; Mosoka Fallah; Gene G Olinger; Fatorma K Bolay; Lisa E Hensley
Journal:  J Virol Methods       Date:  2018-02-23       Impact factor: 2.014

7.  Ten recent articles from the Journal of Hospital Infection that would not have been seen in Issue 1.

Authors:  James Gray
Journal:  J Hosp Infect       Date:  2018-08-01       Impact factor: 3.926
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.